



Neurofibromatosis Type 1 (NF1)

Genetics

Autosomal dominant. Gene localised to 17q11.2. The gene product (neurofibromin) is thought to suppress tumour formation by regulating cell division. A high spontaneous mutation rate means that about half of all cases arise in unaffected families.

Incidence/prevalence

About 1 in 2,500 births.

Physical features

Physical manifestations of NF1 include café-au-lait spots, intertriginous freckling, Lisch nodules (i.e. pigmented iris hamartomas or freckling in the iris), neurofibromas (i.e. benign Schwann cell tumors, divided into four types: (1) focal or diffuse cutaneous, (2) subcutaneous (under the skin), (3) spinal, and (4) nodular or diffuse plexiform neurofibromas, which develop from nerves and extend into surrounding structures, and which can transform into malignant tumours), optic pathway gliomas, and distinctive bone lesions (e.g., short stature or dystrophic scoliosis) (Williams et al., 2009). Diagnosis of NF1 is normally made if two of the following physical manifestations are present – six or more café-au-lait spots, two or more neurofibromas, skinfold freckling, two or more Lisch nodules or a family history of NF1 (Ferner, 2007).

Life expectancy

Depends on nature and severity of clinical features.

Brain abnormalities

Magnetic Resonance Imaging studies revealed many different abnormalities in the brains of NF1-patients. These include T2-hyperintensities (of which the nature is not yet known, and which do not seem to have clinical implications), volumetric abnormalities (mainly enlargements of subcortical structures), white matter abnormalities and differences in functional connectivity. The last three may be related to cognitive and social outcomes (Payne et al., 2010; Loitfelder et al., 2015).

Behavioural characteristics

Many patients experience social and behavioural difficulties (Barton & North, 2004). These include communication difficulties and difficulties forming and maintaining friendships. More than half of children with NF1 show significant scholastic difficulties and more than 30% meet criteria for ADHD. NF1 appears to be even more strongly associated with autism spectrum disorders, with prevalence rates up to 60% (Garg et al., 2013). Cognitive deficits partly underlie the social dysfunctioning observed in NF1 (Huijbregts & De Sonnevile, 2011).

Cognitive characteristics

The global intellectual abilities of individuals with NF1 fall within a normal distribution, albeit towards the lower end of this distribution. In addition, there are high rates of specific neuropsychological

deficits including language, visuo-spatial, attentional, organizational and other executive deficits (Rowbotham et al., 2009).

Treatment

Because of the multi-faceted nature of NF1, treatment is generally aimed at specific symptoms. For example, optic glioma are most often treated with chemotherapy (Ardern-Holmes & North, 2011). Trials are underway with bisphosphonate drugs to treat bone abnormalities (Heervä et al., 2014), whilst Simvastatin was, until now, shown to be ineffective in treatment of cognitive impairment (Van der Vaart et al., 2013). Methylphenidate does seem to ameliorate some of the cognitive symptoms associated with NF1. Trials are currently underway with new medication (Lamotrigine) to improve cognitive and social functioning in NF1 with relatively little attention for non-pharmaceutical interventions.

References

1. Ardern-Holmes SL, & North KN (2011). Therapeutics for childhood Neurofibromatosis Type 1 and Type 2. *Current Treatment Options in Neurology (Pediatric Neurology)* 13, 529-543.
2. Barton B, & North K (2004). Social skills of children with Neurofibromatosis Type 1. *Developmental Medicine & Child Neurology* 46, 553-563.
3. Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, Upadhyaya M, Towers R, Gleeson M, Steiger C, & Kirby A (2007). Guidelines for the Diagnosis and Management of Individuals with Neurofibromatosis 1. *Journal of Medical Genetics* 44, 81-88.
4. Garg S, Green J, Leadbitter K, Emsley R, Lehtonen A, Evans G, & Huson SM (2013). Neurofibromatosis Type 1 and Autism Spectrum Disorder. *Pediatrics* 132, e1642-e1648.
5. Heervä E, Huilaja L, Leinonen P, Peltonen S, & Peltonen J (2014). Follow-Up of Six Patients with Neurofibromatosis 1-Related Osteoporosis Treated with Alendronate for 23 Months. *Calcified Tissue International* 94,608–612.
6. Huijbregts SCJ, & De Sonnevile, LMJ (2011). Does cognitive impairment explain behavioural and social problems of children with Neurofibromatosis Type 1? *Behavior Genetics* 41, 430-436.
7. Hyman S, Shores EA, & North K (2006). Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. *Developmental Medicine & Child Neurology* 48, 973-977.
8. Loitfelder M, Huijbregts SCJ, Veer IM, Swaab HS, Van Buchem MA, Schmidt R, & Rombouts SA (2015). Functional connectivity changes and executive and social problems in Neurofibromatosis Type 1. *Brain Connectivity* 5, 312-320.
9. Payne JM, Moharir MD, Webster R, & North KN (2010). Brain structure and function in neurofibromatosis type 1: current concepts and future directions. *Journal of Neurology Neurosurgery & Psychiatry* 81,304–309.
10. Rowbotham I, Pit-ten Cate IM, Sonuga-Barke EJS, & Huijbregts SCJ (2009) Cognitive control in adolescents with Neurofibromatosis Type 1. *Neuropsychology* 23, 50-60.
11. Van der Vaart T, Plasschaert E, Rietman AB, Renard M, Oostenbrink R, Vogels M-C, De Wit Y, Descheemaeker M-J, Vergouwe Y, Catsman-Berrevoets CE, Legius E, Elgersma Y, & Moll HA (2013). Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA):a randomised, placebo-controlled trial. *Lancet Neurology* 12, 1076-1083.
12. Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, & Maria BL (2009). Neurofibromatosis type 1 revisited. *Pediatrics* 123, 124–133.

Copyright © 2015 S Huijbregts

The SSBP hopes that readers will find the syndrome information sheets useful. They represent the views of the authors who kindly prepared them, and not necessarily those of the SSBP.